title: Prostate specific antigen: an updated review.
abstract: Since its discovery in 1979, serum PSA has revolutionized how physicians manage men with prostate cancer. PSA screening, although currently under much debate, has been recommended by most North American medical bodies, including the Canadian Urological Association, to be performed as a shared-decision making process after discussing with patients the pros and cons of treatment. Although most commonly thought of as a screening tool, serum PSA has also been used to predict tumor volume, stage and prognosis in patients before and after treatment. In this review, we examine PSA testing and its effectiveness in the diagnosis and management of prostate cancer. Further, we also evaluate recent literature regarding the use of PSA derivatives and other prostate cancer markers, such as proPSA, bPSA, and hk2
authors.affiliation: Division of Urology, University of British Columbia, The Prostate Centre at Vancouver General Hospital, Vancouver, BC, Canada.
authors.forename: Alan
authors.initials: A
authors.lastname: So
authors.forename: Larry
authors.initials: L
authors.lastname: Goldenberg
authors.forename: Martin E
authors.initials: ME
authors.lastname: Gleave
mesh_terms: D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000628:therapy; D013997:Time Factors; D020840:Tissue Kallikreins / Q000097:blood
chemical_list: D020840:Tissue Kallikreins; D017430:Prostate-Specific Antigen